In this retrospective histologic study, galectin-3 had a sensitivity of 92% (22/24) Difficulties in the diagnosis of thyroid lesions, even with histologic analysis, are well known. 1,2 Follicular carcinoma presents a particular challenge, with 1 study showing diagnostic discrepancies in 57% of histologic cases of minimally invasive follicular carcinoma reviewed by 5 pathologists. 3 However, papillary carcinoma also can be a diagnostic dilemma. This was demonstrated by a study in which one group of pathologists diagnosed papillary carcinoma in 25% of a set of histologic thyroid samples, while a second group of pathologists diagnosed it in only 4% of the same specimens. 4 These diagnostic challenges have inspired a great deal of research interest in novel methods of correctly identifying thyroid lesions.
In this retrospective histologic study, galectin-3 had a sensitivity of 92% (22/24) for papillary thyroid carcinoma and 44% (4/9) for follicular thyroid carcinoma. Thyroid peroxidase (TPO) had a sensitivity of 50% (12/24) for papillary and 11% (1/11) for follicular carcinoma. The combination of galectin-3 and TPO had a sensitivity of 96% (23/24) for papillary and 44% (4/9) Difficulties in the diagnosis of thyroid lesions, even with histologic analysis, are well known. 1,2 Follicular carcinoma presents a particular challenge, with 1 study showing diagnostic discrepancies in 57% of histologic cases of minimally invasive follicular carcinoma reviewed by 5 pathologists. 3 However, papillary carcinoma also can be a diagnostic dilemma. This was demonstrated by a study in which one group of pathologists diagnosed papillary carcinoma in 25% of a set of histologic thyroid samples, while a second group of pathologists diagnosed it in only 4% of the same specimens. 4 These diagnostic challenges have inspired a great deal of research interest in novel methods of correctly identifying thyroid lesions.
Many immunohistochemical markers have been evaluated to improve the diagnosis of thyroid lesions. 5 Two promising molecular markers are galectin-3 (G3) and thyroid peroxidase (TPO). G3 is member of the galectin family of β-galactoside binding proteins. It has attracted attention as a marker of malignancy owing to its antiapoptotic activity and its role in regulating cell-cell and cell-matrix interaction, adhesion, and migration. [6] [7] [8] [9] [10] Several investigators have examined the usefulness of G3 in thyroid pathology with very encouraging results. [11] [12] [13] [14] [15] [16] In the largest study to date, Bartolazzi and colleagues 17 retrospectively examined histologic and cytologic specimens and prospectively examined cytologic specimens from a wide range of thyroid disorders. Their retrospective evaluation revealed that G3 had a sensitivity between 90% and 94% and a specificity between 94% and 98%. Prospective results were even better, with a sensitivity of 100% and a specificity of 98%. 17 TPO is a thyroid-specific enzyme involved in the synthesis of thyroid hormone. It reflects normal thyroid function and, therefore, should not be expressed in malignant tissue. A number of studies have been published demonstrating the value of TPO in the diagnosis of thyroid lesions, and although the specificities have ranged from 68% to 90%, the sensitivities have consistently been excellent, between 97% and 100%. [18] [19] [20] [21] [22] G3 is a positive marker of malignancy (expressed in cancer but not in benign lesions or normal tissue), while TPO is a negative marker (expressed in benign lesions and normal tissue but not in cancer). These 2 molecular markers, therefore, might be complementary for distinguishing benign from malignant lesions, but to date, no studies have evaluated the value of combining these markers. Also, intuitively it seems that the presence or absence of these markers might give an indication of prognosis. For example, lesions that continue to express TPO would suggest intact thyroid function and a better prognosis than those that do not. To our knowledge, no study has evaluated whether G3 or TPO expression predicts clinical outcome. The aims of the present study were to evaluate the usefulness of evaluating expression of both G3 and TPO in the diagnosis of thyroid neoplasms and to look at patient follow-up data to see whether these markers have prognostic significance.
Materials and Methods
We retrospectively selected tissue blocks from 46 patients who underwent thyroid surgery for benign or malignant disease at the University of Colorado Health Sciences Center, Denver. The 46 specimens included 24 papillary cancers, 9 follicular cancers, and 13 follicular adenomas. All histologic slides were reviewed by 2 pathologists (K.R.S., S.N.) for confirmation of the original diagnosis. At the time of the histologic review, the pathologists had no knowledge of the results of the immunohistochemical studies. All follicular carcinomas and adenomas were blindly rereviewed by 1 pathologist (M.S.S.). The original pathology reports also were reevaluated by 1 pathologist (S.N.).
The tissue blocks were sectioned at 5 µm, deparaffinized in xylene, and rehydrated. Endogenous peroxidase activity was quenched in 3% hydrogen peroxide. Antigen retrieval was performed in a 20-mmol/L concentration of citrate buffer (pH 6.0) for 10 minutes in a Decloaking Chamber (Biocare Medical, Walnut Creek, CA).
Immunohistochemical analysis was performed using an indirect avidin-biotin complex immunoperoxidase method (Vectastain ABC Kit, Vector Laboratories, Burlingame, CA) on a DAKO Autostainer (DAKO, Carpinteria, CA). The primary mouse monoclonal antibodies included anti-G3 antibody (clone B2C10, Research Diagnostics, Flanders, NJ) and anti-TPO antibody (clone TPO 47, Biocytex, Marseilles, France). Following incubation with the primary antibodies for 60 minutes at dilutions of 1:100 (G3) and 1:50 (TPO), sections were reacted with an indirect avidin-biotin-based immunoperoxidase detection system (Vector ABC RTU IgG, Vector Laboratories).
Localization of staining was performed with 3,3'-diaminobenzidine tetrahydrochloride (DAB+, DAKO). The slides were counterstained with hematoxylin (DAKO) and coverslipped using a nonaqueous mounting medium. Purified mouse IgG1 (BD Biosciences, San Diego, CA) at dilutions equivalent to those of the primary antibodies was used as a negative control sample.
Sections from a case of papillary carcinoma of the thyroid that previously was characterized as positive for G3 and adjacent benign thyroid tissue that was known to be negative for TPO were used as positive control samples. The follicular carcinomas were stained twice using the RDI G3 antibody and also were stained with a second mouse monoclonal G3 antibody at a 1:600 dilution (clone 9C4, Novocastra Laboratories, Newcastle upon Tyne, England).
Immunohistochemical staining scores were assigned by 2 pathologists (K.R.S., S.N.). The staining intensity was graded as 0 (no staining), 1+ (slight staining), 2+ (moderate staining), or 3+ (intense staining), and the proportion of stained cells was scored as 1+ (<5% of cells), 2+ (5%-50% of cells), or 3+ (>50% of cells). Cases that showed specific staining of more than 5% of the tumor cells, regardless of staining intensity, were scored as positive for TPO or G3. A positive result for G3 was considered consistent with cancer, and a negative result for TPO was considered consistent with cancer.
Sensitivity, specificity, positive predictive value, and negative predictive value were calculated for G3 and TPO individually and for the 2 antibodies in combination. Sensitivity was defined as the number of carcinomas with positive results (positive G3 or negative TPO) as a percentage of the total number of carcinomas. Specificity was defined as the number of benign lesions with negative results as a percentage of the total number of benign lesions. The positive predictive value was defined as the number of carcinomas with positive results as a percentage of the total number of cases with positive results, and the negative predictive value was defined as the number of benign lesions with negative results as a percentage of the total number of cases with negative results.
To obtain clinical outcome data, a chart review was performed for the 24 cases of papillary thyroid carcinomas. For 6 patients, there was not at least 1 year of clinical follow-up, and the cases were excluded from analysis.
Institutional review board approval was obtained for the staining and chart review portions of the study.
Results

Immunostaining
As shown in ❚Table 1❚, 22 (92%) of 24 papillary carcinomas were positive for G3 ❚Image 1❚. Eighteen tumors had 3+ intensity and a diffuse pattern (grade 3), 2 had 3+ intensity with fewer than 50% of cells staining (grade 2), and 1 had 2+ intensity with a diffuse pattern. One sample showed 1+ intensity with fewer than 50% of cells staining. All of these were considered positive results for the purposes of statistical analysis. Two samples showed no staining.
Of 9 follicular carcinomas, 4 (44%) were positive for G3. One sample showed 3+ intensity with diffuse staining, 1 showed 3+ intensity with fewer than 50% of cells staining, 1 showed 2+ intensity with fewer than 50% of cells staining, and 1 showed 1+ intensity with a diffuse pattern. These 4 samples were considered positive. The remaining 5 follicular carcinomas showed no staining.
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In several papillary and follicular carcinomas, the leading edge of the tumor stained more prominently for G3 than the rest of the tumor ❚Image 2❚. Histiocytes also stained positively for G3 in many samples.
As shown in ❚Table 2❚, the sensitivity of G3 for the detection of any carcinoma was 79%. The sensitivity for papillary carcinoma alone was 92%, while the sensitivity for follicular carcinoma was 44%. The specificity was 69%. The positive predictive value was 87%, and the negative predictive value was 56%.
The specificity of the G3 antibody was demonstrated by Western blot analysis of a papillary carcinoma cell line known to express G3 (NPA) on which the expected single 30-kd band was observed.
As shown in Table 1 ❚Image 1❚ Galectin-3 staining of papillary carcinoma (+) and normal thyroid tissue (-) (×100).
❚Image 2❚ Galectin-3 staining of the leading edge of a papillary carcinoma (×400).
❚Image 3❚ Thyroid peroxidase staining of papillary carcinoma (-) and normal thyroid tissue (+) (×100).
Follicular carcinomas consistently stained strongly with TPO. Of 9 samples, 7 showed 3+ staining intensity with a diffuse pattern, and 1 sample had 2+ intensity with fewer than 50% of cells staining. All were considered positive results. Only 1 follicular carcinoma was negative, showing no TPO staining.
Follicular adenomas consistently stained positively for TPO, with 13 of 13 samples showing 3+ intensity and a diffuse pattern.
By using a negative result for the TPO stain as consistent with cancer, the sensitivity for the detection of any carcinoma was 39% ( Table 2 ). The sensitivity for papillary carcinoma alone was 50%, while the sensitivity for follicular carcinoma was 11%. By using a positive stain for TPO as negative or not suggestive of cancer, the specificity was 100%. The positive predictive value also was 100%, and the negative predictive value was 39%.
The specificity of the TPO antibody was demonstrated through a blocking experiment. A blocking peptide was designed against an epitope (amino acids 713-721) on the TPO protein recognized by the antibody, and when the antibody was preincubated with the blocking peptide, no staining was observed.
The results of the G3 and TPO immunostaining then were combined. A positive result (consistent with cancer) was considered to be either a positive G3 stain or a negative TPO stain. A negative result (not consistent with cancer) was a sample that stained negatively for G3 and positively for TPO. By using these criteria, 23 of 24 papillary carcinomas were positive, giving a sensitivity of 96% (Table 2 ). Of 9 follicular carcinomas, 4 were positive, for a sensitivity of 44%. The overall sensitivity for the detection of any carcinoma was 82%. Of 13 follicular adenomas, 9 had an overall negative combination of stains, giving a specificity of 69%. The positive predictive value of the combination was 87%, while the negative predictive value was 60%.
To ensure that the diagnosis of follicular carcinoma was correct, one pathologist (M.S.S.) rereviewed 8 follicular carcinomas while blinded to the original diagnosis (1 case did not have a full slide set available). Five were still considered follicular carcinoma after rereview. Of the remaining 3 cases, 1 was thought to be a follicular adenoma, 1 was a Hürthle cell carcinoma, and 1 was classified as a follicular adenoma with a microscopic focus of papillary carcinoma. Of the 5 confirmed follicular carcinomas, 3 had negative G3 staining, while 2 were positive (1 with diffuse 3+ intensity staining and 1 with 3+ intensity staining of 5%-50% of the cells). By using these data, the sensitivity for the detection of follicular carcinoma was 40%, whereas the sensitivity using the original pathologic diagnoses was 44%.
G3 and TPO as Markers of Clinical Outcome
At least 1 year of clinical follow-up information was available for 18 of 24 cases of papillary carcinoma. The staining patterns of these 18 cases were as follows: G3-/TPO+, 1 case; G3+/TPO+, 9 cases; G3+/TPO-, 7 cases; and G3-/TPO-, 1 case ❚Figure 1❚. Further clinical outcome analysis was performed on the 16 cases in the 2 largest groups (G3+/TPO+ and G3+/TPO-). Although most of the baseline clinical characteristics were similar between the 2 groups, there was an increased incidence of invasive disease in the G3+/TPO-group compared with the G3+/TPO+ group ❚Table 3❚. Of 9 G3+/TPO+ tumors, 2 (22%) demonstrated invasion. One extended through the thyroid capsule only, and 1 invaded into skeletal muscle. Of 7 G3+/TPO-tumors, 5 (71%) demonstrated invasion. One was through the thyroid capsule only, whereas 4 showed more aggressive invasion, including 1 that invaded adipose tissue, 2 with perineural involvement, and 1 that was "grossly" invasive of adjacent soft tissue. ❚Figure 2❚ shows the initial TNM staging of each group, again reflecting more T4 disease (extension outside the thyroid capsule) in the G3+/TPO-group. No patient had distant metastatic disease (M0) at the time of original diagnosis and treatment.
❚Table 4❚ shows the clinical outcome of the 2 groups. All 9 patients in the G3+/TPO+ group had no evidence of disease at the end of the average follow-up period of 50 months. Of the 9 patients, 6 (67%) became disease-free following thyroidectomy and 1 dose of radioactive iodine (the initial standard treatment for thyroid cancer); 2 (22%) of 9 required 2 doses of radioactive iodine after thyroidectomy to become free of disease; 1 (11%) of 9 required a second neck surgery after initial thyroidectomy and also needed 2 treatments with radioactive iodine to become disease-free. The G3+/TPO-group had an average of 66 months of follow-up. Of the 7 patients, 4 (57%) were diseasefree after initial treatment (thyroidectomy plus radioactive iodine). However, 2 (29%) of 7 had persistent disease at the end of the follow-up period, including 1 patient who required a total of 4 neck surgeries and 4 doses of radioactive iodine and still had an unstimulated thyroglobulin level of 16 ng/mL (16 µg/L). A second patient required a total of 4 neck surgeries and 3 doses of radioactive iodine and still had known neck disease. The final patient (14%) in this group had 2 neck surgeries and 3 treatments with radioactive iodine and developed progressive disease as manifested by lung metastases.
Discussion
In this study, G3 had high sensitivity (92%) for the detection of papillary carcinoma. This is consistent with the near 100% sensitivity previously demonstrated in the literature. [11] [12] [13] [14] [15] [16] [17] The combination of G3 and TPO also was highly sensitive (96%) for the detection of papillary carcinoma. G3 clearly is a useful adjunct to the standard histopathologic diagnosis of papillary thyroid carcinoma. Interestingly, when our samples were broken down into typical papillary carcinoma and follicular variant papillary carcinoma, the sensitivities of G3 alone and the combination of G3 and TPO were 100% and 100%, respectively, for typical papillary carcinoma, and 83% and 92% for follicular variant papillary carcinomas. This would suggest that G3 alone is sufficient for the diagnosis of typical papillary carcinoma, while a better sensitivity for follicular variant papillary carcinoma is obtained with the combination of the 2 antibodies.
Neither G3 nor the combination of G3 and TPO was found to have adequate sensitivity for the detection of follicular carcinoma in this study. The literature is mixed regarding the sensitivity of G3 for follicular carcinoma. Bartolazzi et al 17 reported that 37 of 40 minimally invasive follicular carcinomas (93% sensitivity) and 17 of 17 widely invasive follicular carcinomas (100% sensitivity) were positive for G3. Saggiorato et al 12 similarly found 17 of 17 minimally invasive follicular carcinomas (100% sensitivity) to be positive for G3. These groups used a G3 antibody from Novocastra Laboratories. By using a different G3 antibody (Research Diagnostics), Herrmann et al 13 showed absent or weak staining in their sample of 3 follicular carcinomas and also showed much less staining in their group of follicular variant papillary carcinomas. Fernandez et al 14 and Cvejic et al 15 showed G3 expression in only 4 (50%) of 8 and 11 (73%) of 15 follicular carcinomas, respectively. The results of this study for follicular carcinomas (44% sensitivity) using the Research Diagnostics G3 antibody are more consistent with the results of these last 3 studies and call into question the usefulness of G3 for the diagnosis of follicular carcinoma. It is, however, important to view any results regarding sensitivity for the detection of follicular carcinoma with some caution, because the diagnosis of this entity is notoriously challenging, and it is difficult to be certain of a true "gold standard." 4 Because of the disparate results in the literature, further exploration of the usefulness of G3 staining in follicular carcinoma was undertaken. The follicular carcinomas were restained with the Research Diagnostics antibody, and the same results were observed as with the original staining. The follicular carcinomas also were stained with the Novocastra G3 antibody used by the groups that reported such high sensitivities. Similar staining was observed for both types of antibodies when directly compared on the same follicular carcinoma specimens, with higher background staining with the Novocastra antibody. T2 N0  T2 N1  T3 N0  T3 N1  T4 N0  T4 N1 ❚Figure 2❚ Baseline TNM staging of disease in patients with galectin-3+/thyroid peroxidase (TPO)+ papillary carcinomas (black bars) vs galectin-3+/TPO-papillary carcinomas (white bars).
